According to a recent LinkedIn post from Komprise, genomics research is expected to generate between 2 and 40 exabytes of data over the next decade, citing estimates from the National Human Genome Research Institute. The post notes that, similar to other medical sectors, AI is starting to influence research outcomes and product development in genomics.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights that a key challenge lies in preparing and delivering the right genomics data formats, such as BAM and FASTQ, into AI tools, suggesting that this process is more complex than commonly assumed. The post directs readers to a blog on “cutting-edge practices” in genomics data preparation, indicating a focus on data management capabilities that could position Komprise to benefit from growing AI-driven demand in life sciences.
For investors, the emphasis on large-scale data management in genomics points to a potential growth vertical where Komprise’s unstructured data management platform may have increasing relevance. As AI adoption accelerates in healthcare and genomics, vendors that can efficiently organize, move, and make petabyte- to exabyte-scale data AI-ready could see rising enterprise spend, although the post does not quantify commercial impact or specific customer wins.